Results 151 to 160 of about 34,547 (259)

Association of glucagon‐like peptide‐1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes

open access: yesJournal of Diabetes Investigation, Volume 17, Issue 5, Page 766-780, May 2026.
This TriNetX (US, 2016–2023) study compared clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes treated with GLP‐1 receptor agonists vs DPP4 inhibitors. ABSTRACT Objectives To evaluate whether glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are associated with improved survival and renal outcomes in patients with ...
Yu‐Ting Yu   +4 more
wiley   +1 more source

Association of low‐grade albuminuria and triple‐line pattern as markers of early peripheral vascular remodeling in adolescents with type 1 diabetes

open access: yesJournal of Diabetes Investigation, Volume 17, Issue 5, Page 835-843, May 2026.
In adolescents with type 1 diabetes, the arterial triple‐line pattern (TLP) signals early lower extremity vascular remodeling. Low‐grade albuminuria (UACR ≥15 mg/g) independently predicts TLP, supporting the combined use of these markers to identify subclinical atherosclerosis.
Jung‐Chi Hsu   +7 more
wiley   +1 more source

Clinical Outcomes and Non‐Invasive Testing in Metabolic Dysfunction‐Associated Steatohepatitis With Cirrhosis: A Systematic Review

open access: yesLiver International, Volume 46, Issue 5, May 2026.
ABSTRACT Background and Aims Metabolic dysfunction‐associated steatohepatitis (MASH) with cirrhosis lacks definitive treatments and poses an increasing healthcare burden globally. We undertook a systematic literature review (SLR) to better understand the disease burden in cirrhosis due to MASH.
Hannes Hagström   +8 more
wiley   +1 more source

From Cure to Complexity: Post‐SVR Liver and Metabolic Trajectories in Diabetic Patients

open access: yesLiver International, Volume 46, Issue 5, May 2026.
ABSTRACT Background and Aims The long‐term impact of HCV cure on hepatic and metabolic outcomes in patients with type 2 diabetes (T2D) remains insufficiently defined. This study evaluated T2D‐related vascular complications, liver disease progression and overall survival over 9 years of follow‐up, also exploring genetic variability contribution ...
Clelia Asero   +14 more
wiley   +1 more source

Engineering Marker‐Free Lettuce Chloroplast Genome to Express Functional Glucagon‐Like Peptide‐1 Receptor Agonists Exenatide and Lixisenatide

open access: yesPlant Biotechnology Journal, Volume 24, Issue 5, Page 3158-3171, May 2026.
Engineering of marker‐free lettuce chloroplast genome to express CTB‐Exenatide and CTB‐Lixisenatide for oral delivery. Upper panel: Chemically synthesised exenatide or lixisenatide require expensive production, purification, refrigeration and invasive delivery methods.
Rahul Singh, Henry Daniell
wiley   +1 more source

Podocyte specific knockout (KO) of the natriuretic peptide clearance receptor (NPRC) attenuates diabetic kidney disease (DKD)

open access: yesPhysiological Reports, Volume 14, Issue 9, May 2026.
Abstract Glomerular podocytes play a key role in the pathogenesis of diabetic kidney disease (DKD). Recent studies suggest that natriuretic peptides (NPs) are podocyte protective. The beneficial effects of NPs are inhibited by the removal of NPs from the circulation by the NP clearance receptor (NPRC).
Liming Wang   +4 more
wiley   +1 more source

Associations between glycated albumin and current measures of glycaemic control in Saudi adults. [PDF]

open access: yesFront Endocrinol (Lausanne)
Bahijri S   +6 more
europepmc   +1 more source

Association of Tirzepatide With Kidney Parameters in Participants With Obesity and Prediabetes From SURMOUNT‐1 Over 176 Weeks

open access: yes
Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4400-4404, May 2026.
Hiddo J. L. Heerspink   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy